Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours:: a prospective, randomised, multicentre trial

被引:740
|
作者
van der Zee, J
González, DG
van Rhoon, GC
van Dijk, JDP
van Putten, WLJ
Hart, AAM
机构
[1] Univ Amsterdam, Acad Med Ctr, Subdiv Hyperthermia, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Stat, NL-1105 AZ Amsterdam, Netherlands
来源
LANCET | 2000年 / 355卷 / 9210期
关键词
D O I
10.1016/S0140-6736(00)02059-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Local-control rates after radiotherapy for locally advanced tumours of the bladder, cervix, and rectum are disappointing. We investigated the effect of adding hyperthermia to standard radiotherapy. Methods The study was a prospective, randomised, multicentre trial. 358 patients were enrolled from 1990 to 1996, in cancer centres in the Netherlands, who had bladder cancer stages T2, T3, or T4, N0, M0, cervical cancer stages IIB, IIIB, or IV, or rectal cancer stage M0-1 were assessed. Patients were randomly assigned radiotherapy (median total dose 65 Gy) alone (n=176) or radiotherapy plus hyperthermia (n=182). Our primary endpoints were complete response and duration of local control. We did the analysis by intention to treat. Findings Complete-response rates were 39% after radiotherapy and 55% after radiotherapy plus hyperthermia (p<0.001). The duration of local control was significantly longer with radiotherapy plus hyperthermia than with radiotherapy alone (p=0.04). Treatment effect did not differ significantly by tumour site, but the addition of hyperthermia seemed to be most important for cervical cancer, for which the complete-response rate with radiotherapy plus hyperthermia was 83% compared with 57% after radiotherapy alone (p=0.003). 3-year overall survival was 27% in the radiotherapy group and 51% in the radiotherapy plus hyperthermia group. For bladder cancer, an initial difference in local control disappeared during follow-up. Interpretation Hyperthermia in addition to standard radiotherapy may be especially useful in locally advanced cervical tumours. Studies of larger numbers of patients are needed for other pelvic tumour sites before practical recommendations can be made.
引用
收藏
页码:1119 / 1125
页数:7
相关论文
共 50 条
  • [1] RANDOMISED TRIAL OF RADIOTHERAPY ALONE OR RADIOTHERAPY WITH CARBOGEN AND NICOTINAMIDE IN LOCALLY ADVANCED BLADDER CARCINOMA
    Hoskin, P.
    Rojas, A. M.
    Bentzen, S.
    Saunders, M. I.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S170 - S170
  • [2] Hyperthermia and radiotherapy in pelvic tumours
    van der Zee, J
    González, DG
    RADIATION RESEARCH, VOL 2, CONGRESS PROCEEDINGS, 2000, : 869 - 872
  • [3] A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer
    Harima, Yoko
    Ohguri, Takayuki
    Imada, Hajime
    Sakurai, Hideyuki
    Ohno, Tatsuya
    Hiraki, Yoshiyuki
    Tuji, Koh
    Tanaka, Masahiro
    Terashima, Hiromi
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2016, 32 (07) : 801 - 808
  • [4] Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial
    Li, Z.
    Mao, W.
    Lin, N.
    Han, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (04): : 413 - 417
  • [5] Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial
    Z. Li
    W. Mao
    N. Lin
    S. Han
    Clinical and Translational Oncology, 2016, 18 : 413 - 417
  • [6] Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma
    Ma, J
    Mai, HQ
    Hong, MH
    Min, HQ
    Mao, ZD
    Cui, NJ
    Lu, TX
    Mo, HY
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) : 1350 - 1357
  • [7] Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer
    Oates, GD
    Stenning, SP
    Hardcastle, JD
    McAdam, WAF
    Greaney, MG
    Gunn, A
    Pearson, JB
    Davis, PW
    Kenefick, J
    Postlethwaite, JC
    Bartolo, D
    Williamson, RCN
    Stoddard, CJ
    deCastella, HC
    Dean, ACB
    Thomson, JWW
    Bardsley, D
    Wilkins, JL
    Motson, R
    Foster, GE
    Kane, JF
    Lee, MJR
    HollAllen, RTJ
    Hale, JE
    Davies, GC
    Macleod, IB
    Lallemand, RC
    AlexanderWilliams, J
    Dorricott, NJ
    Keighley, MRB
    Berger, PL
    Goldring, JR
    Miller, DF
    Morran, CG
    Richards, JR
    Thomson, WO
    Madigan, MR
    Kettlewell, MGW
    Mortensen, NJ
    Greatrex, GH
    MacIntyre, IMC
    Blake, JRS
    Doran, J
    Clague, MB
    Cuschieri, A
    Preece, PE
    Smith, JAR
    ThorntonHolmes, J
    Downing, R
    Fielding, JRF
    LANCET, 1996, 348 (9042): : 1605 - 1610
  • [8] Accuracy of pelvic radiotherapy: Prospective analysis of 90 patients in a randomised trial of blocked versus standard radiotherapy
    Huddart, RA
    Nahum, A
    Neal, A
    McLean, M
    Dearnaley, DP
    Law, M
    Dyer, J
    Tait, D
    RADIOTHERAPY AND ONCOLOGY, 1996, 39 (01) : 19 - 29
  • [9] Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)
    Penniment, Michael G.
    De Ieso, Paolo B.
    Harvey, Jennifer A.
    Stephens, Sonya
    Au, Heather-Jane
    O'Callaghan, Christopher J.
    Kneebone, Andrew
    Ngan, Samuel Y.
    Ward, Iain G.
    Roy, Rajarshi
    Smith, Jennifer G.
    Nijjar, Tirath
    Biagi, James J.
    Mulroy, Liam A.
    Wong, Rebecca
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (02): : 114 - 124
  • [10] Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial
    Francois, Eric
    De Bari, Berardino
    Ronchin, Philippe
    Nouhaud, Elodie
    Martel-Lafay, Isabelle
    Artru, Pascal
    Clavere, Pierre
    Vendrely, Veronique
    Boige, Valerie
    Gargot, Deny
    Lemanski, Claire
    Carvalho, Nicolas De Sousa
    Gal, Jocelyn
    Pernot, Mandy
    Magne, Nicolas
    EUROPEAN JOURNAL OF CANCER, 2023, 180 : 62 - 70